Immune Checkpoint Blockade in Melanoma – Earlier is Better?
Administering checkpoint inhibition before surgery, known as neoadjuvant therapy, shows promise in treating bulky yet resectable melanomas, and researchers are investigating its potential in various other cancer types. This approach boasts a considerable success in high pathologic response rate, a...
Saved in:
Main Authors: | Vincas Urbonas, Audrius Dulskas, Edita Baltruškevičienė, Daiva Dabkevičienė |
---|---|
Format: | Article |
Language: | English |
Published: |
Vilnius University Press
2024-09-01
|
Series: | Acta Medica Lituanica |
Subjects: | |
Online Access: | https://www.journals.vu.lt/AML/article/view/32871 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Comparative efficacy and safety of first-line neoadjuvant therapy for early-stage non-small cell lung cancer based on immune checkpoint inhibitor therapy: a systematic review and network meta-analysis
by: Linfeng Wang, et al.
Published: (2025-01-01) -
RECQL4 affects MHC class II‐mediated signalling and favours an immune‐evasive signature that limits response to immune checkpoint inhibitor therapy in patients with malignant melanoma
by: Sara Egea‐Rodriguez, et al.
Published: (2025-01-01) -
Discontinuation of immune checkpoint inhibitors for reasons other than disease progression and the impact on relapse and survival of advanced melanoma patients. A systematic review and meta-analysis
by: Konstantinos Lallas, et al.
Published: (2025-01-01) -
Advances in Cell and Immune Therapies for Melanoma
by: Tanase Timis, et al.
Published: (2025-01-01) -
Efficacy and safety of neoadjuvant immunotherapy combined with chemotherapy for stage II–IVa esophageal cancer: a network meta-analysis
by: Mingxing Wang, et al.
Published: (2025-01-01)